Robin E Gasiorowski - The University of Sydney

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 55 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Nathalie A. Johnson,David Lavie,Peter Borchmann,Gareth P. Gregory,Alex F. Herrera,Leonard Minuk,Vladan Vučinić,Philippe Armand,Abraham Avigdor,Robin Gasiorowski,Yair Herishanu,Colm Keane,John Kuruvilla,Rachel West,Pallavi Pillai,Patricia Marinello,John M. Timmerman

HemaSphereno. S3 (2023): e0274602-e0274602

Cited0Views0Bibtex

Favezelimab (Anti-Lag-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson,Kerry J. Savage,Abraham Avigdor,Ali Bazargan,Peter Borchmann,Robin Gasiorowski,Gareth P. Gregory,Yair Herishanu,Sumit Madan,Leonard Minuk,Gerardo Musuraca,Rachel Marceau West,Pallavi Pillai,Patricia Marinello,Pier Luigi Zinzani

BLOOD (2023)

Cited0Views0Bibtex

Subcutaneous epcoritamab induces durable complete remissions in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: long-term results from the EPCORE NHL-1 Phase 2 expansion cohort

C. W. Scholz, Y. Karimi,H. Ghesquieres, W. Jurczak,C. Y. Cheah,M. R. Clausen,P. Lugtenburg, D. Cunningham,Y. R. Do, D. J. Lewis,R. Gasiorowski,T. M. Kim,M. van der Poel,M. L. Poon,T. Feldman,K. M. Linton,A. Sureda,M. Hutchings, Cota M. Stirner, Y. Liu, N. Kilavuz, M. Sacchi,C. Thieblemont

ONCOLOGY RESEARCH AND TREATMENT (2023): 268-269

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn